search
Back to results

DNA QUANTIFICATION TECHNIQUE AS A INTERPRETATION TOOL IN MITOCHONDRIAL DISEASES

Primary Purpose

Mitochondrial Diseases

Status
Unknown status
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
samples
Sponsored by
Centre Hospitalier Universitaire de Nice
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Mitochondrial Diseases

Eligibility Criteria

undefined - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • general criteria: major or minor patients, sporadic or isolated cases
  • criteria related to pathology:
  • Suspected mitochondrial pathology which will be evaluated according to the following criteria (expertise of the clinician of the MM reference center):
  • Clinical picture suggestive of a mitochondrial pathology ("illegitimate association" of symptoms, specific syndrome of MELAS type for example, muscular deficit, ptosis ...) AND / OR

    • Metabolic assessment suggestive of respiratory tract involvement AND / OR
    • Identification of a deficiency involving one or more complexes of the respiratory chain from a muscular specimen
  • Presence on the histological analysis of the muscle biopsy of COX-negative fibers
  • signing of informed consent for minor patients signed by at least one of the parents or the representative of the parental authority

Exclusion Criteria:

  • Persons deprived of their liberty by a judicial or administrative decision;
  • Persons hospitalized without consent;
  • Persons admitted to a health or social institution for purposes other than research;
  • Persons of legal age who are under protection or who are unable to express their consent. Inability to co-operate.

Sites / Locations

  • CHU de NiceRecruiting

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

biological samples

Arm Description

biological samples on patients with MITOCHONDRIAL DISEASES

Outcomes

Primary Outcome Measures

number of amplification with the NGS technique

Secondary Outcome Measures

comparaison of the number of amplification between NGS technique and the PCR-RFLP technique

Full Information

First Posted
July 7, 2017
Last Updated
July 23, 2018
Sponsor
Centre Hospitalier Universitaire de Nice
search

1. Study Identification

Unique Protocol Identification Number
NCT03216252
Brief Title
DNA QUANTIFICATION TECHNIQUE AS A INTERPRETATION TOOL IN MITOCHONDRIAL DISEASES
Official Title
IMPLEMENTING A SINGLE MUSCLE FIBER DNA QUANTIFICATION TECHNIQUE AS A INTERPRETATION TOOL FOR THE VARIANTS OF UNKNOWN SERVICE IN MITOCHONDRIAL DISEASES
Study Type
Interventional

2. Study Status

Record Verification Date
July 2018
Overall Recruitment Status
Unknown status
Study Start Date
February 2, 2018 (Actual)
Primary Completion Date
July 2019 (Anticipated)
Study Completion Date
July 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire de Nice

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
2622/5000 Mitochondrial diseases (MM) are the most common metabolic diseases. Since these pathologies are very heterogeneous in clinical terms, only the identification of mutations in nuclear genes or mitochondrial DNA confirms the diagnosis. The full-scale study of mtDNA by high-throughput sequencing (NGS) is a first step in the diagnostic approach. The recent introduction of this revolutionary new technology has greatly increased the efficiency of mutation identification. However, in addition to known pathogenic mutations, NGS reveals numerous variants whose significance is currently unknown. A major challenge to obtain a reliable diagnosis is therefore the interpretation of the clinical impact of these new rare variants which proves to be very difficult. Pathogenicity criteria allow the classification of variants from benign to pathogenic. One of the major pathogenicity criteria is a good correlation of heteroplasmic level with tissue or cellular involvement. Indeed, mtDNA mutations are generally heteroplasmic, which corresponds to the coexistence of normal and mutated molecules in the same cell or tissue, the most affected tissues having a high rate of mutation. On a muscle biopsy of an affected patient, the fibers often present an enzyme deficiency in cytochrome c oxidase (COX-negative) which can be demonstrated in immunohistochemistry. The single fiber study allows to isolate the deficient fibers and to quantify the heteroplasmic rate of a variant. The presence of a high level of heteroplasm in the COX-negative fibers, unlike fibers without deficit, is a strong argument in favor of the pathogenicity of this variant. Currently, this technique is not used routinely in diagnostic laboratories but only occasionally in a research framework in some laboratories. It is a heavy technique that consists of a first stage of laser microdissection of the various muscle fibers followed by a second step of quantification of the variant from each fiber. This second step requires a specific focus for each identified variant. The aim of this pilot study is to develop a new technique for quantification of single-fiber heteroplasmics isolated by NGS laser microdissection. This, independent of the type of variant, will avoid the long and costly adjustments required for each new variant identified and thus facilitate its use

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mitochondrial Diseases

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
10 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
biological samples
Arm Type
Other
Arm Description
biological samples on patients with MITOCHONDRIAL DISEASES
Intervention Type
Biological
Intervention Name(s)
samples
Intervention Description
Blood samples, oral smear and urine
Primary Outcome Measure Information:
Title
number of amplification with the NGS technique
Time Frame
36 months
Secondary Outcome Measure Information:
Title
comparaison of the number of amplification between NGS technique and the PCR-RFLP technique
Time Frame
36 months

10. Eligibility

Sex
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: general criteria: major or minor patients, sporadic or isolated cases criteria related to pathology: Suspected mitochondrial pathology which will be evaluated according to the following criteria (expertise of the clinician of the MM reference center): Clinical picture suggestive of a mitochondrial pathology ("illegitimate association" of symptoms, specific syndrome of MELAS type for example, muscular deficit, ptosis ...) AND / OR Metabolic assessment suggestive of respiratory tract involvement AND / OR Identification of a deficiency involving one or more complexes of the respiratory chain from a muscular specimen Presence on the histological analysis of the muscle biopsy of COX-negative fibers signing of informed consent for minor patients signed by at least one of the parents or the representative of the parental authority Exclusion Criteria: Persons deprived of their liberty by a judicial or administrative decision; Persons hospitalized without consent; Persons admitted to a health or social institution for purposes other than research; Persons of legal age who are under protection or who are unable to express their consent. Inability to co-operate.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Cécile ROUZIER
Phone
33 4 92 03 62 43
Email
rouzier.c@chu-nice.fr
Facility Information:
Facility Name
CHU de Nice
City
Nice
ZIP/Postal Code
06200
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Rouzier cecile
Email
rouzier.c@chu-nice.fr

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

DNA QUANTIFICATION TECHNIQUE AS A INTERPRETATION TOOL IN MITOCHONDRIAL DISEASES

We'll reach out to this number within 24 hrs